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From our research and literature search we propose an understanding of the mechanism of action 
of antidepressants treatments (ADTs) that should lead to increase efficacy and tolerance. We 
understand that ADTs promote synaptic plasticity and neurogenesis. This promotion is linked 
with stimulation of dopaminergic receptors. Previous evidence shows that all ADTs (chemical, 
electroconvulsive therapy, repetitive transcranial magnetic stimulation, sleep deprivation) 
increase at least one monoamine neurotransmitter serotonin (5-HT), noradrenaline (NA) or 
dopamine (DA); this article focuses on DA release or turn-over in the frontal cortex. DA increased 
dopaminergic activation promotes synaptic plasticity with an inverted U shape dose–response 
curve. Specific interaction between DA and glutamate is mediated by D1 receptor subtypes and 
Glutamate (NMDA) receptors with neurotrophic factors likely to play a modulatory role. With the 
understanding that all ADTs have a common, final, DA-ergic stimulation that promotes synaptic 
plasticity we can predict that (1) AD efficiency is related to the compound strength for inducing 
DA-ergic stimulation. (2) ADT efficiency presents a therapeutic window that coincides with the 
inverted U shape DA response curve. (3) ADT delay of action is related to a “synaptogenesis 
and neurogenesis delay of action. ” (4) The minimum efficient dose can be found by starting at 
a low dosage and increasing up to the patient response. (5) An increased tolerance requires a 
concomitant prescription of a few ADTs, with different or opposite adverse effects, at a very low 
dose. (6) ADTs could improve all diseases with cognitive impairments and synaptic depression 
by increasing synaptic plasticity and neurogenesis.
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In our working hypothesis, depression is a state of synaptic 
depression brought by a low rate of dopaminergic transmis-
sion with D1 receptor up-regulation that can be reversed by 
an increase in DA transmission. We propose that D1 receptors 
regulate mood. We see depression in a temporal dimension: in 
stressful situations, the organism releases DA in the brain as 
a way to adapt to stressful situations and cortisol release con-
tributes to this adaptation. If this fighting phase is successful the 
person will heal from his stress. In depression this “fighting phase” 
persists and ends in a “loosing phase” in which DA cannot be 
released anymore and D1 receptors are up-regulated. We choose 
to study our hypothesis at the level of the prefrontal cortex 
since this brain area is at the intersection of mood and cogni-
tion and is an essential component for personality integration. 
The prefrontal cortex, receives the projections from the lim-
bic system, may serve to integrate the cognitive and emotional 
information. This area is modulated by NA, serotonin, and DA 
neurotransmission.
Depression as a hypoDopaminergic state
At the pharmacological level, depression is a state involving low 
levels of DA transmission resulting in D1 receptor up-regulation. 
In the rat model of depression, a 4 weeks stress session induces 
a depressive state and reduces DA concentration in the prefron-
tal  cortex  for  3  months  (Mizoguchi  et  al.,  2008b).  Moreover, 
adrenalectomy induces a depressive state with impaired working 
memory (Mizoguchi et al., 2004) and a hypodopaminergic state 
introDuction
Original antidepressants treatments (ADTs) were discovered by 
serendipity and their mechanism of action is still unclear. There is 
a delay of action between chronic ADT administration and patient’s 
response. Side effects differ between ADTs but not with efficiency. 
All chemical ADTs increase at least one monoamine neuromodu-
lator (serotonin, noradrenaline (NA), DA). Assessment of depres-
sion intensity shows that all items of depression scales are strongly 
inter-correlated. The response does not differ with different ADTs 
or with different clinical profiles.
Depression involves emotion, cognition, and physical symptoms. 
Clinical depression is characterized in the DSM-IV-R (APA, 2004) 
by low mood (sadness, loss of motivation, worthlessness/guilt, 
and suicidal ideas), reduced cognition (low psychomotor activ-
ity, fatigue, concentration/attention deficit), and body symptoms 
like retardation, appetite, and sleep changes. Depression is char-
acterized by a reduction of confidence in one-self, the world, and 
the future. Depression is often preceded by a period of acute or 
chronic stress.
Animal models of depression induce low mood (e.g., anhedonia 
can be expressed by reduction in sucrose preference) and psychomotor 
retardation (e.g., reduced reactivity can be expressed by immobility 
in the Porsolt test or escape deficit in the learned helplessness model). 
To induce depression-like behavior, animals are submitted to intense 
stress (unavoidable electric shocks), or chronic mild stress (2 weeks of 
unpredictable changes in the environment). Moreover, stress induces 
DA release in the prefrontal cortex (Del Arco and Mora, 2001).Frontiers in Neuroscience  |  Neuropharmacology    November 2010  | Volume 4  | Article 192  |  2
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 (3)  Administration of ADTs, tianeptine and to a lesser extent 
fluoxetine, reverses the long lasting inhibition of in vivo LTP 
induced by stress in rats (Rocher et al., 2004). In contrast, 
the selective D1 antagonist SKF83566 combined with high-
frequency stimulation by electrode implanted in the corpus 
callosum prevented prefrontal cortex LTP and resulted in 
long term depression (Coppa-Hopman et al., 2009). Together 
these data indicates that D1 receptor activation is necessary 
for the induction of medial prefrontal cortex glutamate-ba-
sed LTP (Gurden et al., 2000; Coppa-Hopman et al., 2009).
all antiDepressants increase Dopamine levels
We  performed  a  literature  search,  retrieving  the  articles  that 
measure DA release in the prefrontal cortex using chemical and 
non-chemical antidepressant treatments. The studies show that, 
in rat, mouse, monkey, and man electroconvulsive therapy (Glue 
et al., 1990; Yoshida et al., 1998; Inoue et al., 2003), repetitive 
transcranial magnetic stimulation (Lisanby and Belmaker, 2000; 
Ohnishi et al., 2004), sleep deprivation (Lara-Lemus et al., 1998; 
Gillin et al., 2001; Wu et al., 2001), and all classes of chemical 
antidepressants, increase DA release in the prefrontal cortex (see 
Table 1). Administration of ADTs was either through ip, po, or 
intra-cortical route. Assessments of DA levels were mostly done 
through in vivo microdialysis.
The following ADTs induce DA release in PFC:
–  From  the “tricyclic”  class:  imipramine  (Jordan  et  al.,  1994; 
Tanda et al., 1994; Valentini et al., 2005), clomipramine (Tanda 
et al., 1994; Owen and Whitton, 2006), desipramine (Carboni 
et al., 1990; Tanda et al., 1994; Gresch et al., 1995; Carlson et al., 
1996; Shoblock et al., 2004; Valentini et al., 2004; Bongiovanni 
et al., 2005), amoxapine (Kobayashi et al., 1992), amitriptiline 
(Kihara and Ikeda, 1995), nortryptiline (Carlson et al., 1996), 
maproptyline (Kihara and Ikeda, 1995).
–  From the “Noradrenalin Serotonin Reuptake Inhibitor” class: 
duloxetine (Carlson et al., 1996; Gobert et al., 1997a,c), mil-
nacipran (Muneoka et al., 2009), venlafaxine (Weikop et al., 
2004).
–  From the “specific serotonin reuptake inhibitor” (SSRI) class: 
fluoxetine (Jordan et al., 1994; Tanda et al., 1994; Gobert et al., 
1997a,b,c, 1999; Pozzi et al., 1999; Millan et al., 2000; Sakaue 
et al., 2000; Bymaster et al., 2002; Koch et al., 2002), citalopram 
(Pozzi et al., 1999; Valentini et al., 2005), paroxetine (Carlson 
et al., 1996; Owen and Whitton, 2006), fluvoxamine (Jordan 
et al., 1994).
–  From  the  “MonoAmine  Oxidase  Inhibitor”  class:  deprenyl 
(Lakshmana  et  al.,  1998),  moclobemide  (Kan  et  al.,  1987), 
IMAO-A (Inoue et al., 2003).
–  From  “Other  ADs”  class:  mianserine  (Tanda  et  al.,  1996a; 
Valentini  et  al.,  2004),  mirtazapine  (Devoto  et  al.,  2004; 
Nakayama  et  al.,  2004),  tianeptine  (Louilot  et  al.,  1990; 
Sacchetti  et  al.,  1993),  amineptine  (Invernizzi  et  al.,  1992; 
Garattini, 1997), agomelatine (Millan et al., 2003), bupropion 
(Li et al., 2002; Inoue et al., 2003), reboxetine (Invernizzi et al., 
2001; Linner et al., 2001; Page and Lucki, 2002; Kitaichi et al., 
2004; Valentini et al., 2004; Carboni et al., 2006; Owen and 
Whitton, 2006).
with a D1 receptor up-regulation (Mizoguchi et al., 2004). This 
  hypodopaminergic function can be reversed by (1) D1 agonists, 
(2) DA release, and (3) ADT administration.
(1)  Infusion of a D1 agonist, SKF81297, in the rat prefrontal cor-
tex, reverses the working memory impairment due to adrena-
lectomy (Mizoguchi et al., 2004), and the rotarod impairment 
due to both chronic stress (Mizoguchi et al., 2002) and adre-
nalectomy (Mizoguchi et al., 2008a). Furthermore, working 
memory is enhanced in naïve, non-depressed rats, 12 h after 
learning  (Floresco  and  Phillips,  2001).  Other  specific  D1 
receptor agonists A68930 (D’Aquila et al., 1994), and the 
partial agonist SKF38393 (D’Aquila et al., 1994; Gambarana 
et al., 1995; Takamori et al., 2001), reverse, after the first 
administration,  the  escape  deficit  induced  by  the  learned 
helplessness model of depression. SKF38393 also reduces the 
spontaneous escape deficit of rats not exposed to the inesca-
pable shocks (Gambarana et al., 1995). When given repeate-
dly this D1 agonist produces tolerance to its own protective 
effect. Indeed, long term administration of this selective D1 
agonist is known to down-regulate D1 receptors number in 
the prefrontal cortex (Gambarana et al., 1995). The specific 
D1 receptor antagonist SCH23390 reverses the effects of SKF 
38393, (Takamori et al., 2001) and completely antagonized 
the effect of a chronic-2-weeks-imipramine treatment in the 
learned helplessness model of depression (D’Aquila et al., 
1994). It is of interest to see that ADT is suppressed by D1 
antagonist.
(2)  DA challenge, with 30 mg of d-amphetamine induces a lar-
ger mood elevating effect, in unmedicated depressed patients 
when compared to controls. Controls are healthy volunteers 
without history of axis I disorders in DSM-IV-R (Tremblay 
et al., 2005). This mood enhancing DA challenge could indi-
cate that D1 receptors are up-regulated during depression 
and more sensitive to DA increase.
(3)  Chronic ADT treatment with imipramine reverses the escape 
deficit induced by the learned helplessness model of depres-
sion  (D’Aquila  et  al.,  1994;  Gambarana  et  al.,  1995)  and 
down regulates D1 receptor number in the prefrontal cortex 
(Gambarana et al., 1995).
At the cellular level depression may be a state of depressed synap-
tic plasticity that can be reversed by (1) D1 agonist administration, 
(2) DA release, and (3) AD treatments.
 (1)  The  selective  D1  receptor  agonist,  SKF81297  at  an  opti-
mal  dose  facilitates  long  term  potentiation  (LTP)  in  the 
  hippocampal–prefrontal  cortex  pathway  whereas  the  D1 
antagonist SCH23390 caused a dose-related impairment of 
its induction (Gurden et al., 2000).
 (2) DA released from DArgic axon terminals in the prefrontal 
cortex facilitates synaptic plasticity whereas a depletion of 
cortical DA levels generates a dramatic decrease in this LTP 
(Gurden et al., 1999). Magnitude of this prefrontal LTP is 
also enhanced by clozapine and this effect is reversed by 
the D1 receptor antagonist SCH23390 (Matsumoto et al., 
2008).www.frontiersin.org  November 2010  | Volume 4  | Article 192  |  3
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Table 1 | Prefrontal dopamine release from antidepressant treatment.
Reference  Antidepressant dosage/administration  Prefrontal dopamine increase (I) from antidepressant
ElEcTRocoNvulsIvE ThERAPy (EcT)
Inoue et al. (2003)  ECT  I
Yoshida et al. (1998)  1–8 ECS  I from first ECT
Glue et al. (1990)  1–8 ECS  I from first ECT
REPETITIvE TRANsmAgNETIc sTImulATIoN (rTms)
Ohnishi et al. (2004)  rTMS in right primary motor cortex, 5 Hz  I in the mesolimbic pathway
Lisanby and Belmaker (2000)  rTMS chronic  I dopamine content and turn over rate
slEEP dEPRIvATIoN 
Lara-lemus et al. (1998)  REM sleep deprivation 48 h  I: +33%
Gillin et al. (2001)  Total sleep deprivation in men (eight papers)  I endogenous release of dopamine
Wu et al. (2001)  Total Sleep Deprivation in men, one night (seven papers)  dopamine release was associated with AD
chEmIcAl Ads 
Tricyclic
Valentini et al. (2005)  Imipramine  I
Jordan et al. (1994)  Imipramine  I
Tanda et al. (1994)  Imipramine 10 mg/kg  I
Tanda et al. (1994)  Clomipramine 10 mg/kg  I
Owen and Whitton (2006)  Clomipramine (1–7 days)  I after day 7
Bongiovanni et al. (2005)  Desipramine 10–20 mg  I
Tanda et al. (1994)  Desipramine 10 mg  I
Gresch et al. (1995)  Desipramine 1 μM ic  I: +149%
Gresch et al. (1995)  Desipramine + tail shock  I: +584%
Valentini et al. (2004)  Desipramine  I dose dependently
Carlson et al. (1996)  Desipramine 10 mg, 21 days  I
Carboni et al. (1990)  Desipramine  I
Shoblock et al. (2004)  Desipramine  I
Tanda et al. (1996)  Desipramine 10 mg 1 day (and chronic 14 days)  I: +300%
    I: +300%
Kobayashi et al. (1992)  Amoxapine Acute, chronic  I (same level during acute and chronic treatment)
Kihara and Ikeda (1995)  Amitriptyline 6–25 mg per os  I
Carlson et al. (1996)  Nortryptiline 10 mg  I
Kihara and Ikeda (1995)  Maproptyline  I
IRsN
Gobert et al. (1997b)  Duloxetine 5 mg  I: +115%
Gobert et al. (1997a)  Duloxetine 5 mg  I: +65%
Kihara and Ikeda (1995)  Duloxetine 3–12 mg  I
Muneoka et al. (2009)  Milnacipran  I
Weikop et al. (2004)  Venlafaxine 10 mg  I: +200%
ssRI
Gobert et al. (1997b)  Fluoxetine  I: +55%
Pozzi et al. (1999)  Fluoxetine 10 or 25 mg  I: +167% or +205%
Pozzi et al. (1999)  Fluoxetine 25 mg + PCPA  I: +202% (same level with and without PCPA)
Sakaue et al. (2000)  Fluoxetine  I
Koch et al. (2002)  R-fuo  I
Bymaster et al. (2002)  Fluoxetine acute  I
Bymaster et al. (2002)  Citalopram, Fluvoxamine, Paroxetine, Sertraline acute  No I for the four ADs at the dosage used
Gobert et al. (1997a)  Fluoxetine 10 mg  I: +60%
Gobert et al. (1997a)  Fluoxetine + Buspirone  I: +240%
Gobert et al. (1997c)  Fluoxetine10 mg  I: +200%
Jordan et al. (1994)  Fluoxetine ip  I
  Fluoxetine ic  I
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Tanda et al. (1994)  Fluoxetine   I
Gobert and Millan (1999)  Fluoxetine 10 mg  I: +55%
  Fluoxetine + buspirone  I: +300%
  Fluoxetine + raclopride  I: +90%
Millan et al. (2000)  Fluoxetine   I
Tanda et al. (1996)  Fluoxetine 5 mg acute  I: +200%
  Fluoxetine 10 mg, 14 days)  I: +200%
Pozzi et al. (1999)  Citalopram 25 mg/kg  I: +216%
Pozzi et al. (1999)  Citalopram 25 mg/kg + PCPA  I: 211% same level without (+191%) PCPA
Valentini et al. (2005)  Citalopram  No I
Valentini et al. (2005)  Paroxetine 10 mg  I
Nakayama (2002)  Paroxetine  I
Nakayama (2002)  Paroxetine + granisetron  Granisetron (5HT3−) inhibit paroxetine effect
Carlson et al. (1996)  Paroxetine 10 mg, 21 days  I
Owen and Whitton (2006)  Paroxetine 10 mg  I
Jordan et al. (1994)  Fluvoxamine ic  I
mAoI
Inoue et al. (2003)  IMAO  I
Lakshmana et al. (1998)  Deprenyl 0.25 mg 8 days  I: +87%
Lakshmana et al. (1998)  Deprenyl + clorgyline 1 mg  I: +245%
Kan et al. (1987)  Moclobemide  I dose-dependent
others
Valentini et al. (2004)  Mianserine  I
Tanda et al. (1996)  Mianserine 1–10 mg  I: +600%
Nakayama et al. (2004)  Mirtazapine 4–16 mg  I
Devoto et al. (2004)  Mirtazapine 5–10 mg  I, DOPAC
Devoto et al. (2004)  Mirtazapine + ic desipramine)  I Additional increase dopamine and DOPAC
Millan et al. (2000)  Mirtazapine acute and chronic  I
Sacchetti et al. (1993)  Tianeptine 10  I
Louilot et al. (1990)  Tianeptine 10–20 mg acute  I
  Tianeptine chronic  I in DOPAC less pronounced after 15 days
Millan et al. (2003)  Agomelatine  I
Invernizzi et al. (1992)  Amineptine 5–20 mg/kg  I at 10–20 mg, no I at 5 mg
Garattini (1997)  Amineptine  I
Li et al. (2002)  Bupropion 10 mg/kg  I +260%
Li et al. (2002)  Bupropion + fluoxetine 10 mg  I: +357%
Inoue et al. (2003)  Bupropion  I
Kitaichi et al. (2004)  Reboxetine acute 0, 3–20 mg  I
Kitaichi et al. (2004)  Reboxetine + Sub Li  I
Carboni et al. (2006)  Reboxetine  I
Invernizzi et al. (2001)  Reboxetine 10 mg, 2–14 days  I: +257% at day 2 and I: +342% at day 14
Page and Lucki (2002)  Reboxetine 20 mg  I (no I at 10 mg)
Page and Lucki (2002)  Reboxetine + tailpinch stress  I with reboxetine not in saline
Linner et al. (2001)  Reboxetine 15–13, 5 mg ip  I
  Reboxetine 333 μM ic  I
Valentini et al. (2004)  Reboxetine  I
Owen and Whitton (2006)  Reboxetine 10 mg acute  I
Owen and Whitton (2006)  Reboxetine chronic 4–21 days  I (gradual increase up to day 7)
Owen and Whitton (2006)  Reboxetine + amantadine  I (Amantadine increases speed and intensity)
Table 1 | Continued
Reference  Antidepressant dosage/administration  Prefrontal dopamine increase (I) from antidepressant
Table 1 indicates that all ADTs, irrespective of their   mechanism 
of action, (electroconvulsive therapy, repetitive transcranial mag-
netic  stimulation,  sleep  deprivation,  and  all  chemical  class  of 
  antidepressants), induce DA release in the prefrontal cortex. They 
also increase DA in other brain areas like the limbic system, the 
nucleus accumbens, the striatum, and other cortical regions, but the www.frontiersin.org  November 2010  | Volume 4  | Article 192  |  5
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2005) and haloperidol (Carboni et al., 1990; Ago et al., 2005) 
enhance fluvoxamine-induced DA release. In addition, halo-
peridol (Carboni et al., 1990) enhances desmethylimipramine 
and oxaproptiline-induced DA release. All antipsychotics that 
share a common D2 and 5HT2C receptor antagonism should 
increase DA release. Indeed, zotepine (Nakamura et al., 2005), 
risperidone (Huang et al., 2006), and clozapine (Zhang et al., 
2000)  enhance  prefrontal  DA  concentration.  Risperidone 
(Huang  et  al.,  2006)  and  olanzapine  (Zhang  et  al.,  2000) 
enhance AD-induced DA release. The olanzapine + fluoxetine 
combination (Zhang et al., 2000) increases prefrontal DA by 
360% compared to baseline. This combination was significan-
tly greater than either drug alone.
–  Selective or mixed agonists of the 5HT1A receptor increase 
prefrontal DA release: pindolol (Gobert and Millan, 1999), 
buspirone (Tanda et al., 1994; Gobert et al., 1997a; Sakaue 
et al., 2000), 8-OH-DPAT (Gobert et al., 1998, 1999; Hughes 
et al., 2005), flibanserin (Invernizzi et al., 2003). In contrast, 
specific 5HT1A antagonists WAY100635, decreases prefron-
tal DA that was previously increased either by imipramine 
(Valentini et al., 2005), mirtazapine (Nakayama et al., 2004), 
or by the association of sulpiride and fluvoxamine (Ago et al., 
2005).
–  Direct perfusion of the 5-HT3 agonist, N-methylquipazine, 
in the anterior medial prefrontal cortex produces a concen-
tration-dependent increase in extracellular DA level (Kurata 
et al., 1996). A recent review (Rajkumar and Mahesh, 2010) 
proposed that 5-HT3 receptor could mediate the SSRI effect. 
5HT3 antagonist, ICS205930, prevents the DA increase due 
to fluoxetine or desipramine when infused in the prefrontal 
cortex or when administered systemically (Tanda et al., 1995) 
and Granisetron reduces the DA increase due to paroxetine 
(Nakayama, 2002). The 5HT3 antagonist, BRL4647OA, pro-
duces a dose dependent decrease of DA when infused in the 
anterior medial prefrontal cortex (Kurata et al., 1996).
Drugs known to increase the speed or efficiency of AD response 
also increase DA in the prefrontal cortex: lithium (Morissette and 
Paolo, 1996; Kitaichi et al., 2005), pindolol (Gobert and Millan, 
1999; Millan and Gobert, 1999), idazoxan (Gresch et al., 1995; 
Weikop et al., 2004), buspirone (Tanda et al., 1994; Gobert et al., 
1997a; Sakaue et al., 2000), yohimbine (Tanda et al., 1996a; Millan 
et al., 2000). Those drugs, also potentiate the DA increases due 
to  ADs:  chronic  lithium  increases  milnacipran-induced  DA 
release (Kitaichi et al., 2005), pindolol potentiates fluoxetine- and 
  duloxetine-induced DA release (Gobert and Millan, 1999), yohim-
bine increases fluoxetine-induced DA release (Millan et al., 2000). 
Buspirone augments duloxetine-induced DA up to 550% (Gobert 
et al., 1997a) and fluoxetine-induced DA up to 300% (Gobert et al., 
1997a; Gobert et al., 1999). Idazoxan with venlafaxine increases DA 
up to 200% (Weikop et al., 2004). These compounds also act to 
block their respective 5HT and NE autoreceptors.
Other drugs or hormones increase DA in the prefrontal cortex 
and present AD efficiency. This is the case for cortisol (Imperato 
et al., 1989; Mizoguchi et al., 2004, 2008a), estrogen, (Dazzi et al., 
2007) thyroid hormones (Watanabe, 1999), substance P (Cador 
et al., 1989), and nicotine. Nicotine (Shearman et al., 2005; Tsukada 
increase was not as systematic as in the frontal cortex. DA increases 
with the first ADT administration and is kept at this increased level 
during chronic treatment. Acute ADT treatment releases DA in the 
same range as a 2–3 weeks chronic treatment (Tanda et al., 1996b; 
Page and Lucki, 2002). DA release is increased by 50–600%, depend-
ing on the type of ADT and on the dosage of ADT that is admin-
istered. From these data, we could predict the “strength” of an ADT 
(speed/efficacy) on its capacity to increase DA levels in the prefrontal 
cortex. In some studies using SSRI, it was found that a low ADT 
dosage does not produce the expected increase in DA, while higher 
dosages of ADTs do induce the increase in DA (Invernizzi et al., 
1992; Pozzi et al., 1999; Valentini et al., 2005). As mentioned above, 
the increase in DA could be a direct pharmacological effect (e.g., 
imipramine is an inhibitor of DA reuptake) or could result from 
an indirect mechanism. For example, sleep deprivation increases 
the release of thyroid and estrogen hormones (Baumgartner et al., 
1993), which in turn can enhance DA release, and SSRI can release 
DA through 5HT3 receptors activation in prefrontal cortex (Tanda 
et al., 1995).
Some receptors are specifically implicated in this DA increase. 
Pharmacological experiments show that DA release can be attrib-
uted to specific receptor activation or deactivation. Table 2 shows, 
in animals, that alpha 2, 5HT3, 5HT1A, 5HT2C, D2 receptors can 
mediate the release of DA. DA increases when blocking Alpha 2, 
5HT2C, and D2 receptors at a low dose. DA is also increased when 
activating the 5HT1A, and maybe the 5HT3 receptors. In contrast 
agonists of Alpha 2, 5HT2C, and D2 receptors and antagonists of 
5HT1A and 5HT3 receptors reduce DA release.
Table 2 indicates: 
–  Antagonists of the Alpha 2 receptor, idazoxan (Gresch et al., 
1995; Weikop et al., 2004), yohimbine (Tanda et al., 1996a; 
Millan et al., 2000), fluparoxan (Millan et al., 2000), atipe-
mazole  (Gobert  et  al.,  1997c),  1-(2-pyrimidinyl)piperazine 
(Gobert et al., 1997c, 1999), RX821002 (Gobert et al., 1998), 
BRL44408 (Gobert et al., 1998) increase prefrontal DA release. 
Conversely, receptor agonists: clonidine (Gresch et al., 1995; 
Tanda  et  al.,  1996a;  Devoto  et  al.,  2004),  demedetomidine 
(Gobert et al., 1998), guanabenz (Gobert et al., 1998), S18616 
(Gobert et al., 1997c) reduce prefrontal DA release.
–  Antagonist of the 5HT2C receptor, SB206553 (Gobert et al., 
2000), SB242084 (Millan et al., 1998; Gobert et al., 2000) incre-
ase prefrontal DA, while 5HT2C receptor agonists decrease 
prefrontal DA (Millan et al., 1998; Gobert et al., 2000).
–  Selective or mixed receptors antagonists of the D2 receptor 
increase prefrontal DA: raclopride (Gobert et al., 1998, 1999) 
haloperidol (Carboni et al., 1990). The atypical antipsychotic 
drug risperidone, a multireceptor antagonist, which lacks 5-HT6 
receptor antagonist properties, at doses of 0.1, 0.3, and 1.0 mg/kg, 
produces a bell-shaped dose response effect on DA efflux in the 
prefrontal (Li et al., 2007). Conversely, the selective D2/3 ago-
nist CGS 15855A decreases DA by 50% (Gobert et al., 1998). 
Interestingly, neuroleptic augmentation of ADT treatment has 
been used in severely depressed patients with good results. 
The explanation might be that neuroleptic (D2 antagonists) 
increase DA release and therefore are likely to augment ADT 
response. Indeed the studies show that sulpiride (Ago et al., Frontiers in Neuroscience  |  Neuropharmacology    November 2010  | Volume 4  | Article 192  |  6
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Table 2 | Prefrontal dopamine release from compounds.
Reference  Receptor activation  compound alone  dopamine increase  compound with drug:increase (I) or 
      (I) or decrease (d)  decrease (d) compared to drug alone
Weikop et al. (2004)  Alpha2−  Idazoxan 1, 5 mg  I  I: venlafaxine + 200%
Gresch et al. (1995)    Idazoxan ic 0, 1–5 nM  I 
Gobert and Millan (1999)    1-PP  I: +90%  I: fluoxetine + 200%
Tanda et al. (1996a)    Yohimbine  I 
Millan et al. (2000)    Yohimbine  I  I: fluoxetine
Millan et al. (2000)    Fluparoxan  I  I: fluoxetine
Gobert et al. (1997b)    Atipamezole  I: +180%  I: duloxetine + 370%
        I fluoxetine + 170%
Gobert et al. (1997b)    1-PP 2, 5 mg  I: +90%  I: duloxetine + 600%
Gobert et al. (1998)    RX821,002  I: +73% 
Gobert et al. (1998)    BRL44408  I: +85% 
Gresch et al. (1995)  Alpha 2+  Clonidine 0, 2 mg  D  D: fluoxetine/buspirone
Tanda et al. (1996a)    Clonidine  D 
Devoto et al. (2004)    Clonidine 0, 15 mg ip    D: mirtazapine
Gobert et al. (1997b)    S 18616  D: −51% 
Gobert et al. (1998)    Dexmedetomidine  D: −45% 
Gobert et al. (1998)    Guanabenz  D: −50% 
Gobert and Millan (1999)    S18616    D: fluoxetine/buspirone
Tanda et al. (1996a)  5HT2−  Ritanserine 1 mg  No I  I: yohimbine
Gobert et al. (2000)    5HT2A  No I 
    MDL100907   
Gobertet al.  (2000)    5HT2C/B  I 
    SB206553   
Gobert et al. (2000)    5HT2C  I 
    SB 242084   
Gobert et al. (2000)    5HT2B  No I 
    SB204741   
Millan (1998)    5HT2C–  I 
    SB 242084   
Millan (1998)  5HT2+  5HT2C+  D 
    Ro600175   
Gobert et al. (2000)    5HT2C+  D 
    Ro600175   
Gobert and Millan (1999)  5HT1a+  Pindolol  I  I: fluoxetine 
        I: duloxetine
Millan and Gobert (1999)    Pindolol  I 
Gobert et al. (1997a)    Buspirone 2, 5 mg  I: 100%  I: duloxetine + 550%
        I: Fluoxetine + 240%
Tanda et al. (1994)    Buspirone 1 mg  I 
Sakaue et al. (2000)    Buspirone  I 
Gobert et al. (1997b)    Buspirone  I: +100%  I: fluoxetine + 300%
Gobert et al. (1997b)    8-OH-DPAT  I: +135%  I: fluoxetine
Hughes et al. (2005)    8-OH-DPAT 0, 3 mg  I  I: paroxetine + 400%
Sakaue et al. (2000)    MKC242: 0, 3–1 mg  I 
Invernizzi et al. (2003)    Flibanserin 10 mg  I: +63% 
Gobert et al. (1998)    8-OH-DPAT  I: +100% 
Ago et al. (2005)  5HT1a–  WAY100635    D: sulpiride/fluvoxamine
Valentini et al. (2005)    WAY100635    D: imipramine
Invernizzi et al. (2003)    WAY100635    D: flibanserin 10 mg
Nakayama et al. (2004)    WAY 100635    D: mirtazapine
(Continued)www.frontiersin.org  November 2010  | Volume 4  | Article 192  |  7
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Gobert et al. (1998)  5HT1b+  GR46611  No I 
Gobert et al. (1998)  5HT1b−  GR127 ,935  No I 
Kurata et al. (1996)  5HT3+  N-methylquipazine ic  I: dose dependent 
Nakayama (2002)  5HT3−  Granisetron    D: paroxetine
Tanda et al. (1995)    ICS 205930 ic and ip    D: fluoxetine
Kurata et al. (1996)    BRL46470A ic  D: dose dependent 
Rivet et al. (1998)  5HT  PCPA 20 mg    Despite PCPA, ADs induce DA increase: 
        fluoxetine + 85%, duloxetine + 350%, 
        desipramine + 290%  
        mirtazapine + 300% fluoxetine + 202%  
        citalopram + 211%
Gobert et al. (1998)  D2+  CGS15855A  D:−50% 
Gobert and Millan (1999)  D2−  Raclopride 16 mg/kg  I: +60% 
Gobert et al. (1998)    Raclopride  I:+60% 
Ago et al. (2005)    Sulpiride 10 mg  No I  I: fluvoxamine 10 mg
Ago et al. (2005)    Haloperidol 1 mg    I: fluvoxamine 10 mg
Carboni et al. (1990)    Haloperidol  I  I: desmethylimipramine 
        I: oxaproptiline
Nakamura et al. (2005)  Atypical Antipsy  Zotepine 10 mg  I   
  chotique 
  D2– and 5HT2−
Huang et al. (2006)    Risperidone 1 mg  I  I: citalopram 10 mg
Zhang et al. (2000)    Olanzapine    I: fluoxetine  +360%
        I: sertraline
Valentini et al. (2004)    Clozapine  +DOPA 
Owen and Whitton (2006)  NMDA antagonist  Amantadine 40 mg/kg  No I  I: reboxetine
        I: clomipramine
        I: paroxetine
Toide (1990)    Amantadine 40 mg/kg  I: +16% 
Owen and Whitton (2006)    Budipine 10 mg/kg  No I  I: reboxetine
        I: clomipramine
        I: paroxetine
Spanagel (1994)    Memantine 5–20 mg  I: +50% 
Hesselink (1999)    Memantine  No I 
Shearman et al. (2006)    Memantine  I 
Kitaichi et al. (2005)  Li  Lithium (7 days)    I: milnacipran
Morissette and Paolo (1996)    LiCl 10 mEq  I 
Watanabe (1999)  Hormones  Thyroid hormone T3    I: desipramine
Dazzi et al. (2007)    Estrogen: estrous cycle  I: Estrus 
      D: Proestrus 
Morissette and Paolo (1996)    Estrogen E2  No I  I: Li
Mizoguchi et al. (2008)    Adrenalectomy  D 
Mizoguchi et al. (2004)    Adrenalectomy  D 
    Cortisol  I 
    Replacement   
Imperato et al. (1989)    Corticoïd  I 
Table 2 | Continued
Reference  Receptor activation  compound alone  dopamine increase  compound with drug:increase (I) or 
      (I) or decrease (d)  decrease (d) compared to drug alone
et al., 2005) and anticholinesterase drugs such as galantamine (Noda 
et al., 2010; Schilstrom et al., 2007) and donepezil (Shearman et al., 
2006), enhance extracellular levels of DA in the medial prefron-
tal cortex. In addition, anticholinesterase treatment presents AD 
properties (Tanaka et al., 2004; Rozzini et al., 2007; Cummings 
et al., 2008) and anticholinesterase augmentation of AD treatment 
improves the response in depressed patients (Pelton et al., 2008) 
and the release of DA in the prefrontal cortex (Wang et al., 2007a). 
The pro-cognitive effect of anticholinesterase drugs could rely on 
the synaptic potentiation of the D1/NMDA activation, since the Frontiers in Neuroscience  |  Neuropharmacology    November 2010  | Volume 4  | Article 192  |  8
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infused in the prefrontal cortex (Gurden et al., 2000; Matsumoto 
et al., 2008). Conversely D1 antagonist reverses the D1 agonist 
effect on LTP (Gurden et al., 2000; Matsumoto et al., 2008; 
Coppa-Hopman et al., 2009). D1/NMDA activation is required 
for synaptic plasticity. Our working hypothesis proposes that 
depression is a state of synaptic depression and that AD induces 
synaptic potentiation. Both emotional and cognitive aspects of 
depression rely on synaptic plasticity. The hypothesis predicts 
several characteristics for AD activity: the AD response should 
(1) be non-specific (same efficacy for all types of depressions), 
(2) be global (all items of the depression scales should improve 
together), (3) be regulated inside a physiological range, (changes 
in synaptic plasticity are kept under strict homeostatic regula-
tion), (4) needs time to archive the changes in synaptic plasticity 
(delay of action of AD), and (5) depends on a correct dosage 
(too little or too much AD should be ineffective, they should be 
a therapeutic window). All those five points are demonstrated 
in the literature.
(1)  Non-specific
(a)  All characterized types of depression respond the same 
way to an AD treatment (Lavergne et al., 2005). ADs 
improve identically the different forms of clinically cha-
racterized depression (melancholy, atypical depression, 
recurrent depression, post partum depression, seasonal 
depression,  previous  suicide  attempts,  bipolar  spec-
trum), only severe depression with psychotic symptoms 
responded less to 30 mg/day of mirtazapine and possi-
bly did not reach the synaptic potentiation state. (b) The 
healing process in depression is identical under AD tre-
atment compared to placebo. Patients, with and without 
AD treatment, present the same response profile when 
healing. With placebo only the less depressed patients 
respond (Rabkin et al., 1987). ADs increase the speed 
of response and allows response in severely depressed 
patients.
(2)  Global
Clinicians  know  that  mood  and  psychomotor  retardation 
improve together when the patient respond. The global AD 
effect is demonstrated by the fact that all ADs, despite diffe-
rent lateral effects, induce a parallel decrease of all depression 
scale items in clinical trials. Before and during treatment all 
depression items are strongly inter-related.
(3)  Regulated inside a physiological range
The range goes from synaptic depression to synaptic poten-
tiation.  The  outside  of  the  D1/NMDA  inversed  U  curve 
corresponds to a state of synaptic depression; the inside of 
the curve corresponds to a state of synaptic potentiation. 
An argument to believe that AD efficacy is limited inside 
a physiological range is the limitation of the AD response. 
At the end of a 6 weeks-AD treatment (mirtazapine), the 
remission rate (stable response with > 50% MADRS score 
decrease) is only 30.9% (Lavergne et al., 2005). The benefit 
of treatment is to facilitate a state of synaptic potentiation. 
ADs cannot modulate mood higher. The state of synaptic 
potentiation is, with time, reduced by D1 receptors down-
regulation. The slowdown in improvement observed after 
D1 antagonist, SCH23390, and not the muscarinic acetylcholine 
receptor antagonist, scopolamine, reverses the cognitive improve-
ment due to galantamine in an animal model of Alzheimer’s disease 
(Wang et al., 2007b). The D1 antagonist, SCH23390 also abolishes 
the pro-cognitive effect of the galantamine–risperidone associa-
tion in a chronic phencyclidine model of cognitive deficit (Wang 
et al., 2007a).
Dopamine moDulation of neuroplasticity in 
Depression
Pharmacological evidence for a role of D1 receptors in the bidi-
rectional modulation of synaptic plasticity in the prefrontal cortex 
has been demonstrated in the past few years by different groups 
including ours. DA through D1 receptors increases NMDA currents 
and this synergism which occurs at the postsynaptic level appears to 
be mediated through both a PKA and Ca2+-dependent mechanisms 
(Jay et al., 1998; Gurden et al., 1999, 2000; Jay, 2003; Kruse et al., 
2009). In addition, DA through D1 receptors appears to control the 
rate of phosphorylation/dephosphorylation of NMDA and AMPA 
receptor subunits which is required for a functional NMDA receptor 
(Sun et al., 2005; Gao and Wolf, 2008). D1 receptors may facilitate 
LTP by increasing the AMPA receptor pool available for synap-
tic insertion. Conversely, stimulation of D2 receptors decreased 
surface and synaptic GluR1 expression. Abnormal engagement of 
such mechanism could account for the maladaptive plasticity of 
prefrontal cortex, an area that we identified to be a target for inter-
vention in stress-relates disorders like depression (Rocher et al., 
2004; Cerqueira et al., 2007; Caudal et al., 2010). Emerging findings 
reveal that ADT treatment enhance membrane expression of AMPA 
receptors and phosphorylation of GluR1 subunit in the prefrontal 
cortex and hippocampus (Martinez-Turrillas et al., 2002, 2007; Qi 
et al., 2009). The mechanisms involved in the synaptic targeting of 
AMPA receptors by desipramine and paroxetine, ADs which dif-
ferentially affect monoamine reuptake (NA and 5-HT), are similar 
but not identical. The mechanisms activated by these ADs could 
lead to an enhanced neuronal plasticity probably underlying, at 
least in part, the clinical efficacy of ADs treatment. A coordinated 
activation of DA D1 and NMDA systems is also an important fea-
ture of adaptive behavior. The processing of working memory in 
the mPFC involves DA D1 receptors that depend, at least in part, 
of NMDA receptors activity in this cortical area.
In our understanding of the AD-induced DA changes, the DA 
enhancement provides an AD effect through its interaction with 
NMDA receptors. The direct action on the NMDA receptors could 
bypass the DA increase and induce a strong AD response (Pacher 
et al., 2001; Skolnick et al., 2009; aan het Rot et al., 2010). On the 
other hand, the DArgic-antidepressant mechanism could provide a 
regulation that may be protective for the neuron: the DA inverted U 
dose–response curve of NMDA effects could bring some regulation 
and prevent toxic response.
Working hypothesis: Depression as a synaptic long 
term Depression state
As we have seen in the prefrontal cortex, DA-induced activation 
of NMDA receptors could be the final common pathway for AD 
treatments (Lavergne and Jay, 2009). LTP is facilitated, in naïve 
rats, when DA is released (Jay et al., 2004) or when D1 agonist is www.frontiersin.org  November 2010  | Volume 4  | Article 192  |  9
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(5)  Therapeutic window
The D1/NMDA inversed U response curve implies a mini-
mum and a maximum therapeutic dose. It predicts a thera-
peutic window for the AD response. It is intuitive that too 
low  dosage  would  be  inefficacious  and  less  intuitive  and 
that high dosage could be detrimental on efficacy. Too low 
dosage could be archived by interrupting the monoamine 
pathway.  Catecholamine  and  tyrosine  depletion  induce  a 
depressive relapse, within a few hours, in recently remitted 
depressed patients (Heninger et al., 1996; Delgado et al., 
2002). We speculate that an interruption of transmission in 
the monoamine pathways or administration of a D1 antago-
nism could treat a manic episode. Tyrosine depletion decre-
ases the release of DA produced by amphetamine (McTavish 
et al., 2001). The same amino acid mixture lacking tyro-
sine and its precursor phenylalanine lowers both subjec-
tive and objective measures of the psychostimulant effect 
of methamphetamine (McTavish et al., 2001) and impairs 
spatial recognition memory and spatial working memory 
in volunteers (Harmer et al., 2001). It also reduces mania 
ratings  in  bipolar  patients  (McTavish  et  al.,  2001).  High 
AD dosage or high blood concentration of AD in patients 
with low drug metabolism, may compromise the response. 
High blood concentration of amitriptyline compromises the 
therapeutic effect in depressed patients. The data support 
the existence of a therapeutic window (70–220 ng/ml) for 
amitriptyline  serum  level  (Ulrich  et  al.,  2001).  Moreover 
high blood concentration of paroxetine and desipramine 
compromises the benefit of treatment in patients with panic 
disorder (Watanabe et al., 2007) and the analgesia in chronic 
back pain (Atkinson et al., 2007). Future research is needed 
to more precisely test the hypothesis that high dosage of D1 
agonist compromises AD activity in an animal model of 
depression.
neW prescription strategy for antiDepressant 
treatment
The D1/NMDA inversed U dose–response curve predicts a thera-
peutic window. To reach the therapeutic window we recommend 
to start the prescription at a low dosage (from 1/10 to 1/3 of the 
usually recommended dosage) and to increase the dosage, every 
4–7 days, until the patient presents a qualitative positive change in 
his mood and functioning. This progressively incremental dosage 
will find the “minimal individual effective dosage.” The progressive 
increase will likely reduce the adverse effects intensity and might 
reduce the speed of the D1 receptors down-regulation, providing 
a longer D1/NMDA activation. In our practice we expect a small 
improvement after 3–7 days of treatment in mildly depressed 
young patients and expect the improvement to take longer in 
severely older depressed patients. However, the AD dosage should 
start at a higher level in severely depressed patients compared to 
less depressed patients.
One can take advantages of the fact that different monoam-
ines pathways can increase DA release. A new strategy for AD 
treatment is to mix low doses of AD to augment efficiency and 
tolerance. This strategy can increase efficacy if the mixed ADs 
have synergetic effects on DA release and increases tolerance 
the first 2 weeks of treatment presumably results from home-
ostatic   counter-regulation. In fact most of the AD response 
occurs before the counter-regulation. All the ADs studied in 
the mirtazapine French regulatory “dossier de transparence” 
were pooled in a meta-analysis. At 2-week the score decrease 
was 60% of the end-point score decrease (Lavergne and De 
Mouzon, 2000), indicating that most of the score decrease 
occurs before the second week of treatment. The AD activity 
is limited by the D1/NMDA inversed U curve and by the D1 
receptors down-regulation. Subsequent improvement relies 
on the new positive life experiences that are now possible in 
a state of synaptic potentiation.
Another argument to believe that AD activity is kept within 
homeostatic regulation is the lack of perception of an AD 
effect.  Patients  and  healthy  volunteers  perceive  the  AD 
effect like a global positive mood change “more good days 
than usual” and do not perceives a “high” like with alcohol, 
cocaine…
(4)  Time needed to archive synaptic potentiation
Changes, from synaptic depression to synaptic potentia-
tion, takes time, and likely more time when the patient 
is in a profound state of synaptic depression. This would 
explain the AD delay of action. Animals and healthy volun-
teers respond to ADs within 3 h, while it takes longer for 
depressed patients to respond to ADs. In animal models of 
depression, the behavioral effects can be measured 20 min 
after AD administration and the increased synaptogenesis 
and neurogenesis can be measured after 2–3 h. Behavioral 
changes, in healthy volunteers, are noticed 3 h after admi-
nistration  of  the ADs  (Harmer  et  al.,  2003a,b;  Tse  and 
Bond, 2003). In all clinical trials with ADs, the depression 
scales’ score decrease is larger in the first half of treatment 
compared to the second half. The speed of improvement, 
measured as the score change per day, is maximal in the 
first week of treatment (2.65%/day, on the Montgomery 
Asberg Depression Rating Scale). The improvement period 
(rate  of  improvement  >  2%/day)  lasted  only  2  weeks. 
Subsequent improvement was much slower (<0.5%/day). 
The AD activity is not delayed but is time-limited (Berlin 
and Lavergne, 1998). In clinical trials the AD improvement 
is observed after 4 days. In the Zurich meta-analysis, Angst 
and coworkers (Stassen et al., 1993, 1996) found that the 
score decrease in the AD group differs from the placebo 
group starting on the fourth day of treatment. After 1 week 
clinicians can usually observe the patient’s improvement. 
In a mirtazapine study, 50% of the 4771 depressed patients 
present, a “little improvement” after 1-week treatment (one 
point increase or more with the Clinical Global Impression 
Scale) and a 18.5% score decrease with the Montgomery 
Asberg Depression Rating Scale. Another argument that 
points toward early AD effect is that an improvement pre-
dicts the final response. A “one point increase or more” on 
the  Clinical  Global  Impression-Improvement  scale  was 
found to allow correct classification of responders in 71.6% 
of the patients when the response was defined as a “50% 
score  reduction  in  the  Montgomery  Asberg  Depression 
Rating Scale” (Lavergne et al., 2005).Frontiers in Neuroscience  |  Neuropharmacology    November 2010  | Volume 4  | Article 192  |  10
Lavergne and Jay  Dopamine theory of depression
references
aan het Rot, M, Collins, K. A., Murrough, J. 
W., Perez, A. M., Reich, D. L., Charney, 
D. S., and Mathew, S. J. (2010). Safety 
and efficacy of repeated-dose intra-
venous ketamine for treatment-
resistant depression. Biol. Psychiatry 
67, 139–145.
Ago, Y., Nakamura, S., Baba, A., and 
Matsuda, T. (2005). Sulpiride in 
combination  with  fluvoxamine 
increases in vivo dopamine release 
selectively in rat prefrontal cor-
tex. Neuropsychopharmacology 30, 
43–51.
APA (2004). DSM IV-R. Masson: APA.
Atkinson, J. H., Slater, M. A., Capparelli, E. 
V., Wallace, M. S., Zisook, S., Abramson, 
I., Matthews, S. C., and Garfin, S. R. 
(2007). Efficacy of noradrenergic 
and  serotonergic  antidepressants 
in chronic back pain: a preliminary 
concentration-controlled trial. J. Clin. 
Psychopharmacol. 27, 135–142.
Baumgartner, A., Dietzel, M., Saletu, B., 
Wolf, R., Campos-Barros, A., Graf, 
K. J., Kurten, I., and Mannsmann, 
U. (1993). Influence of partial sleep 
deprivation on the secretion of thy-
rotropin, thyroid hormones, growth 
hormone, prolactin, luteinizing hor-
mone, follicle stimulating hormone, 
and estradiol in healthy young women. 
Psychiatry Res. 48, 153–178.
Berlin, I., and Lavergne, F. (1998). Early 
predictors of two month response 
with mianserin and selective serotonin 
reuptake inhibitors and influence of 
definition of outcome on prediction. 
Eur. Psychiatry 13, 138–142.
Bongiovanni, R., Kirkbride, B., Walmire, 
P., and Jaskiw, G. E. (2005). Tyrosine 
administration  does  not  affect 
desipramine-induced dopamine lev-
els as measured in vivo in prefrontal 
cortex. Brain Res. 1054, 203–206.
Bymaster, F. P., Zhang, W., Carter, P. 
A., Shaw, J., Chernet, E., Phebus, L., 
Wong, D. T., and Perry, K. W. (2002). 
Fluoxetine, but not other selective 
serotonin uptake inhibitors, increases 
norepinephrine and dopamine extra-
cellular levels in prefrontal cortex. 
Psychopharmacology  (Berl.)  160, 
353–361.
Cador, M., Rivet, J. M., Kelley, A. E., Le Moal, 
M., and Stinus, L. (1989). Substance P, 
neurotensin and enkephalin injections 
into the ventral tegmental area: com-
parative study on dopamine turnover 
in several forebrain structures. Brain 
Res. 486, 357–363.
Carboni, E., Silvagni, A., Vacca, C., and Di 
Chiara, G. (2006). Cumulative effect of 
norepinephrine and dopamine carrier 
blockade on extracellular dopamine 
increase in the nucleus accumbens 
shell, bed nucleus of stria terminalis 
and prefrontal cortex. J. Neurochem. 
96, 473–481.
Carboni, E., Tanda, G. L., Frau, R., and 
Di Chiara, G. (1990). Blockade of 
the noradrenaline carrier increases 
extracellular dopamine concentra-
tions in the prefrontal cortex: evi-
dence that dopamine is taken up 
in vivo by noradrenergic terminals. J. 
Neurochem. 55, 1067–1070.
Carlson, J. N., Visker, K. E., Nielsen, D. 
M., Keller, R. W. Jr., and Glick, S. D. 
(1996). Chronic antidepressant drug 
treatment reduces turning behavior 
and increases dopamine levels in the 
medial prefrontal cortex. Brain Res. 
707, 122–126.
Caudal, D., Mailliet, F., Bergerot, D., 
Watilliaux, A, and Jay, T. M. (2010). 
“PO113.2:  acute  stess  induces 
opposite changes in AMPA recep-
tor  subunits  phosphorylation  in 
prefontal cortex and amygdala,” in 
7th Forum of European Neuroscience 
(Amsterdam), 167.
Cerqueira, J. J., Mailliet, F., Almeida, O. 
F., Jay, T. M., and Sousa, N. (2007). 
The prefrontal cortex as a key target 
of the maladaptive response to stress. 
J. Neurosci. 27, 2781–2787.
Coppa-Hopman,  R.,  Galle,  J.,  and 
Pimkine, D. (2009). D1 receptor antag-
onist-induced long-term depression 
in the medial prefrontal cortex of rat, 
in vivo: an animal model of psychiatric 
hypofrontality. J. Psychopharmacol. 23, 
672–685.
Cummings, J. L., Mackell, J., and Kaufer, 
D. (2008). Behavioral effects of cur-
rent Alzheimer’s disease treatments: a 
descriptive review. Alzheimers Dement. 
4, 49–60.
D’Aquila, P. S., Collu, M., Pani, L., 
Gessa, G. L., and Serra, G. (1994). 
Antidepressant-like effect of selective 
dopamine D1 receptor agonists in the 
behavioural despair animal model of 
depression. Eur. J. Pharmacol. 262, 
107–111.
Dazzi, L., Seu, E., Cherchi, G., Barbieri, P. 
P., Matzeu, A., and Biggio, G. (2007). 
Estrous cycle-dependent changes in 
basal and ethanol-induced activity 
of cortical dopaminergic neurons in 
the rat. Neuropsychopharmacology 32, 
892–901.
Del Arco, A., and Mora, F. (2001). 
Dopamine release in the prefrontal 
cortex during stress is reduced by the 
local activation of glutamate receptors. 
Brain Res. Bull. 56, 125–130.
Delgado, P. L., Moreno, F. A., Onate, L., 
and Gelenberg, A. J. (2002). Sequential 
catecholamine and serotonin deple-
tion in mirtazapine-treated depressed 
patients. Int. J. Neuropsychopharmacol. 
5, 63–66.
Devoto, P., Flore, G., Pira, L., Longu, G., 
and Gessa, G. L. (2004). Mirtazapine-
induced corelease of dopamine and 
noradrenaline from noradrenergic 
neurons in the medial prefrontal and 
occipital cortex. Eur. J. Pharmacol. 487, 
105–111.
Ferreri, M., Lavergne, F., Berlin, I., Payan, 
C., and Puech, A. J. (2001). Benefits 
from mianserin augmentation of 
fluoxetine in patients with major 
depression non-responders to fluox-
etine alone. Acta Psychiatr. Scand. 103, 
66–72.
Floresco, S. B., and Phillips, A. G. (2001). 
Delay-dependent modulation of 
memory retrieval by infusion of a 
dopamine D1 agonist into the rat 
medial prefrontal cortex. Behav. Brain 
Res. 115, 934–939.
Gambarana,  C.,  Ghiglieri,  O.,  and 
Graziella de Montis, M. (1995). 
Desensitization of the D1 dopamine 
receptors in rats reproduces a model of 
escape deficit reverted by imipramine, 
conclusion
Our research and literature search indicate that (1) D1 receptors 
activation (D1 stimulation, DA availability in the prefrontal cortex), 
is the common denominator of all AD treatments (2) depression 
appears as a state of D1 receptor deactivation (D1 up-regulation with 
little DA availability). In our working hypothesis depression is a state 
of synaptic depression that can be reversed by AD treatment. Indeed 
ADs promote synaptic potentiation. All ADs enhance DA release in 
the prefrontal cortex. Activation of D1 receptors induces NMDA 
activation and an enhancement of synaptic potentiation through 
an inverted U dose–response curve that could represent a form of 
mood regulation. The mood improvement, with ADs, has to be in 
a physiological range, being maximal at the start of treatment and 
reduced thereafter because of D1 receptors down-regulation.
Based on this understanding, we propose a new strategy for 
prescribing Ads which consists on a progressive escalating dosage 
of an association of ADs. Mixing ADs with opposite side effects 
should increase tolerance. Mixing ADs with synergistic mechanism 
on DA release should increase efficacy. The strength of an AD can 
be assessed by the DA release in the prefrontal cortex. The benefit 
of AD treatment can be valuable in all states of cognitive deficits, 
even in non-depressed patients.
if the ADs have   opposite side effects. Efficacy: AD of different 
mechanisms of action, and drugs known to enhance speed and 
efficacy of AD response, have synergistic effects on DA release. 
See Table 2. For example, monoamine reuptake inhibitors could 
be co-prescribed with one or two AD with other mechanism of 
action (monoamine-oxidase inhibitor, 5-HT2C antagonist, alpha 
2 antagonist, 5-HT1A agonist), to promote DA increase. The ben-
efit of AD association has been tested. Mianserine augmentation 
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previously not responding to fluoxetine alone (Ferreri et al., 2001). 
Tolerance: Increasing tolerance requires concomitant prescrip-
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prescribed ADs should have different – and ideally opposite – 
types of side effect. For example, three ADs each given at a third 
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For example, sedative antidepressants can be co-prescribed with 
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appetite increasing ADs, libido decreasing ADs can be prescribed 
with libido increasing ADs. The new strategy predicts that mixing 
different ADs increases efficacy and tolerance.www.frontiersin.org  November 2010  | Volume 4  | Article 192  |  11
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